Table 2.
Frequency of and change in SLICC criteria in CLE to SLE patients at baseline visit and visit of SLE diagnosis
| SLICC Criteriaa | Initial Visit n, (%) | Visit of SLE diagnosis n, (%) | Increase between visits n, (%) |
|---|---|---|---|
| Leukopenia | 1 (10%) | 4 (40%) | 3 (30%) |
| Thrombocytopenia | 1 (10%) | 4 (40%) | 3 (30%) |
| Synovitis | 0 (0%) | 2 (20%) | 2 (20%) |
| Chronic cutaneous lupus | 8 (80%) | 10 (100%) | 2 (20%) |
| Oral/Nasal ulcers | 2 (20%) | 3 (30%) | 1 (10%) |
| Low Complement | 2 (20%) | 3 (30%) | 1 (10%) |
| Antiphospholipid | 0 (0%) | 1 (10%) | 1 (10%) |
| Lymphopenia | 1 (10%) | 2 (20%) | 1 (10%) |
| Anti-dsDNA | 1 (10%) | 2 (20%) | 1 (10%) |
| ANA | 8 (80%) | 9 (90%) | 1 (10%) |
| Acute cutaneous lupus | 3 (30%) | 3 (30%) | 0 (0%) |
| Anti-Sm | 1 (10%) | 1 (10%) | 0 (0%) |
a
SLICC criteria not listed were not present in patients who progressed from CLE to SLE.
Abbreviations: ANA, anti-nuclear antibody, anti-Sm, anti-Smith antibody, CLE, cutaneous lupus erythematosus, dsDNA, double-stranded DNA antibody, SLE, systemic lupus erythematosus, SLICC, Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus,